newsfilter
← Latest News
PR Newswire·

PDL BioPharma to Exchange Approximately 80% of Convertible Notes Due 2021 and 2024

PDL BioPharma, Inc. ("PDL" or the "Company") (Nasdaq: PDLI) today announced that it has entered into separate, privately negotiated exchange...